Navigation Links
Bayer Expands Its Hemophilia Leadership Development Program
Date:2/2/2012

WAYNE, N.J., Feb. 2, 2012 /PRNewswire/ -- To further its commitment to the hemophilia community, Bayer HealthCare is expanding the Bayer Hemophilia Leadership Development Program (BHLDP) by adding a community element to the internship experience.  The 2012 interns selected to participate in this prestigious program will spend five weeks of the eight-week program at a local hemophilia organization. 

The company is currently seeking applicants who are attending college and have been touched by hemophilia.  Those interested have until Monday, March 12th to apply for the program, which runs from June 18th-August 9th.  Participating interns will engage in leadership training, hands-on business projects, marketing and communications strategies, and help support the local hemophilia community.  Additional details and the application can be found at www.livingbeyondhemophilia.com/intern.

Of the many organizations that applied to participate, four chapters were chosen to mentor and manage an intern.  They are the Arizona Hemophilia Association, Bleeding Disorders Alliance Illinois, Hemophilia Foundation of Upstate New York – Rochester and Texas Central Hemophilia Association.

"Bayer is proud to offer this program, which is unique in the hemophilia community," said Leslie Donato, Vice President/General Manager, Hematology, Bayer HealthCare.  "It's dedicated to creating future hemophilia leaders through hands-on experience and collaboration with local chapter personnel and Bayer colleagues."

The 2012 program begins with a two-week orientation at Bayer HealthCare's U.S. headquarters in Wayne, NJ, where the interns will receive training on communications, problem solving and leadership skills as well as work with people in a number of departments to gain insights into how various parts of the company operate.  Interns will spend the follow
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Phase III Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera
2. Phase 3 Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
3. Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy
4. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
5. Intendis, Inc. Changes Name to Bayer HealthCare
6. Bayers Xarelto® (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis
7. Bayers Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
8. Bayer HealthCare LLC Stops Trademark Infringement by Indian Pharmaceutical Company
9. Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement
10. Bayer HealthCares MEDRAD and Nuance Communications Unveil Industrys First(1) Solution to Automate CT Contrast-Injection Documentation at the annual Radiology Society of North America (RSNA) Meeting
11. Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  MedVantx, Inc., the company that has pioneered ... today the Company has completed a major expansion of ... products and the upgrade of its systems to offer ... its specialty home delivery pharmacy in Sioux ... manufacturers, physicians, health systems and payors novel distribution services, ...
(Date:5/23/2013)...  Echo Pharma Acquisition Limited ("Royalty Pharma") announced today ... Threshold from 90 percent to 50 percent of Maximum ... with the terms of the Revised Offer Document issued ... Under the terms of the Increased Offer, Royalty Pharma ... ) for $12.50 per share in cash. The Increased ...
(Date:5/23/2013)... May 23, 2013  PAREXEL International Corporation (NASDAQ: ... presenting at the Jefferies Healthcare Conference in New York.  ... and Chief Financial Officer, will be making a presentation ... on Monday, June 3, 2013. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
Breaking Medicine Technology:MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10PAREXEL International To Present At Jefferies Healthcare Conference 2
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... for life science companies, today announced that Kevin Hrusovsky, President ... BioConference Live event, which was held on October 26, and ... Forum on October 27 held at Harvard Medical School. ...
... Conn., Nov. 7, 2011 Boehringer Ingelheim Pharmaceuticals, Inc. ... a Phase 2b study, SOUND-C2, that showed the combination ... compounds – the protease inhibitor BI 201335 and the ... successful in reducing viral load below the lower limit ...
Cached Medicine Technology:Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 3Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 4Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 5
(Date:5/23/2013)... May 23, 2013 The vast majority ... deal of control over their level of physical activity, ... far fewer are actually taking that control. Those ... Council (IFIC) Foundation’s 2013 Food & Health Survey. , ... it’s possible to have “a great deal of control” ...
(Date:5/23/2013)... New York (PRWEB) May 23, 2013 ... protecting the rights of victims injured by defective medical ... Litigation Counsel Matthew J. McCauley has been appointed Co-Lead ... Re: Mirena IUD Products Liability Litigation (Case 7:13-md-02434-CS). The ... Co-Lead and Liaison Counsel are to submit their proposal ...
(Date:5/23/2013)... 23 (HealthDay News) -- Symptoms of borderline personality ... complicating diagnosis and treatment. But researchers in Canada ... be unique to borderline personality disorder: a tendency ... , "They have difficulty processing facial emotions and ... face," said Anthony Ruocco, a clinical neuropsychologist and ...
(Date:5/23/2013)... isolated from a person who died from H7N9 avian ... and be transmitted between ferrets. Ferrets are often used ... transmission of influenza virus between ferrets can provide clues ... in people. The research was supported, in part, by ... of the National Institutes of Health. , The researchers ...
(Date:5/23/2013)... CT (PRWEB) May 23, 2013 Six ... a million dollars by Lyme Research Alliance, the nation's ... major academic institutions. The studies focus on the epidemiology of, ... diseases.  , “LRA is proud to support the ... and the brightest men and women in the field ...
Breaking Medicine News(10 mins):Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3Health News:Ferrets, pigs susceptible to H7N9 avian influenza virus 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 4
... Reporter , TUESDAY, Aug. 3 (HealthDay News) -- Foreign-born ... medical degrees abroad performed as well or better than ... analyzed records on nearly 250,000 patients hospitalized for a ... 2003-2006. The study included more than 6,100 doctors, including ...
... (Boston) - Investigators from the Slone Epidemiology Center at ... African American women who use oral contraceptives have a ... The study results, recently published on-line in Cancer ... from the Black Women,s Health Study (BWHS), a large ...
... have found a new mechanism that explains how certain ... infections or pathological antibodies such as those present in ... is published online in the September issue of ... MD, Professor of Medicine at Mount Sinai School of ...
... Association of Specialty Professors (ASP) has announced the ninth ... investigators will join 75 previous T. Franklin Williams Scholars ... the capacity of internal medicine subspecialists to care for ... two- to four-year career development awards funded by generous ...
... of cancer are rapidly changing the clinical practice of ... of cancer, the development of new tools capable of ... tissue will become essential to the success of genetically ... at UCLA have now developed a microfluidic image cytometry ...
... Gardner HealthDay Reporter , MONDAY, Aug. 2 (HealthDay ... largely vegetarian diet and were breast-fed until the age of ... European city who ate a Western diet and were breast-fed ... that dominated those small Western stomachs may predispose these children ...
Cached Medicine News:Health News:Foreign-Trained Doctors As Good As U.S.-Trained Counterparts 2Health News:Foreign-Trained Doctors As Good As U.S.-Trained Counterparts 3Health News:Oral contraceptive use associated with increased risk of breast cancer 2Health News:New drug target for immune diseases discovered 2Health News:ASP announces 2010 T. Franklin Williams Scholars 2Health News:New diagnostic chip able to generate single-cell molecular 'fingerprints' for brain tumors 2Health News:New diagnostic chip able to generate single-cell molecular 'fingerprints' for brain tumors 3Health News:Western Diet Populates Kids' Stomachs With Bad Bacteria 2Health News:Western Diet Populates Kids' Stomachs With Bad Bacteria 3
... The Macula Plus® 5.5 ... observation of the optic ... Use it with your ... detecting choroidal neovascular membranes, ...
... iQ200 Automated Urine Microscopy Analyzer (iQ200) ... (APR) software to classify urine particles ... results. The iQ200 eliminates most technologist ... particle images by automating specimen preparation, ...
... is based on the C6 peptide antigen, a ... VlsE. This peptide has been shown to ... all of the antigenic reactivity of the whole ... C6 peptide is a sensitive and specific marker ...
First to USA-market, this revolutionary technology combines CBC and CRP analysis for stat results of 17 parameters within 4.5 minutes!...
Medicine Products: